{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T21:33:31Z","timestamp":1791236011149,"version":"4.1.0"},"reference-count":148,"publisher":"Springer Science and Business Media LLC","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2004,4]]},"DOI":"10.1602\/neurorx.1.2.213","type":"journal-article","created":{"date-parts":[[2004,3,30]],"date-time":"2004-03-30T22:38:21Z","timestamp":1080686301000},"page":"213-225","source":"Crossref","is-referenced-by-count":356,"title":["Cerebrospinal fluid protein biomarkers for Alzheimer\u2019s disease"],"prefix":"10.1007","volume":"1","author":[{"given":"Kaj","family":"Blennow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"10200213_CR1","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/00001504-199907000-00019","volume":"12","author":"K Blennow","year":"1999","unstructured":"Blennow K, Skoog I. Genetic testing for Alzheimer\u2019s disease: how close is reality?Curr Opin Psychiatry 12: 487\u2013493, 1999.","journal-title":"Curr Opin Psychiatry"},{"key":"10200213_CR2","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/0022-510X(70)90063-8","volume":"11","author":"BE Tomlinson","year":"1970","unstructured":"Tomlinson BE, Blessed G, Roth M. Observations on the brains of demented old people.J Neurol Sci 11: 205\u2013242, 1970.","journal-title":"J Neurol Sci"},{"key":"10200213_CR3","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1212\/WNL.38.11.1688","volume":"38","author":"L Davies","year":"1988","unstructured":"Davies L, Wolska B, Hilbich C, Multhaup G, Martins R, Simms G et al. A4 amyloid protein deposition and the diagnosis of Alzheimer\u2019s disease: prevalence in aged brains determined by immunocytochemistry compared with conventional neuropathologic techniques.Neurology 38: 1688\u20131693, 1988.","journal-title":"Neurology"},{"key":"10200213_CR4","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1212\/WNL.34.7.939","volume":"34","author":"G McKhann","year":"1984","unstructured":"McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer\u2019s disease: report of the NINCDS-ADRDA Work Group under the auspices of department of health and human services task force on Alzheimer\u2019s disease.Neurology 34: 939\u2013944, 1984.","journal-title":"Neurology"},{"key":"10200213_CR5","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1001\/archneur.56.3.303","volume":"56","author":"RC Petersen","year":"1999","unstructured":"Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome.Arch Neurol 56: 303\u2013308, 1999.","journal-title":"Arch Neurol"},{"key":"10200213_CR6","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S1474-4422(03)00262-X","volume":"2","author":"C DeCarli","year":"2003","unstructured":"DeCarli C. Mild cognitive impairment: prevalence, prognosis, aetiology, and treatment.Lancet Neurol 2: 15\u201321, 2003.","journal-title":"Lancet Neurol"},{"key":"10200213_CR7","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1177\/002383099200500208","volume":"5","author":"K Blennow","year":"1992","unstructured":"Blennow K, Wallin A. Clinical heterogeneity of probable Alzheimer\u2019s disease.J Geriatr Psychiatry Neurol 5: 106\u2013113, 1992.","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"10200213_CR8","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/j.1460-2075.1989.tb03390.x","volume":"8","author":"M Goedert","year":"1989","unstructured":"Goedert M, Spillantini MG, Potier MC, Ulrich J, Crowther RA. Cloning and sequencing of the cDNA encoding an isoform of microtubule-associated protein tau containing four tandem repeats: differential expression of tau protein mRNAs in human brain.EMBO J 8: 393\u2013399, 1989.","journal-title":"EMBO J"},{"key":"10200213_CR9","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0165-0173(00)00019-9","volume":"33","author":"L Bu\u00e9e","year":"2000","unstructured":"Bu\u00e9e L, Bussiere T, Buee-Scherrer V, Delacourte A, Hof PR. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders.Brain Res Brain Res Rev 33: 95\u2013130, 2000.","journal-title":"Brain Res Brain Res Rev"},{"key":"10200213_CR10","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/978-3-7091-6139-5_29","volume":"62","author":"K Iqbal","year":"2002","unstructured":"Iqbal K, Alonso Adel C, El-Akkad E, Gong CX, Haque N et al. Pharmacological targets to inhibit Alzheimer neurofibrillary degeneration.J Neural Transm Suppl 62: 309\u2013319, 2002.","journal-title":"J Neural Transm Suppl"},{"key":"10200213_CR11","doi-asserted-by":"crossref","first-page":"4913","DOI":"10.1073\/pnas.83.13.4913","volume":"83","author":"I Grundke-Iqbal","year":"1986","unstructured":"Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI. Abnormal phosphorylation of the microtubule-associated protein \u03c4 (tau) in Alzheimer cytoskeletal pathology.Proc Natl Acad Sci USA 83: 4913\u20134917, 1986.","journal-title":"Proc Natl Acad Sci USA"},{"key":"10200213_CR12","first-page":"213","volume":"59","author":"K Iqbal","year":"2000","unstructured":"Iqbal K, Alonso AD, Gondal JA, Gong CX, Haque N, Khatoon S et al. Mechanism of neurofibrillary degeneration and pharmacologic therapeutic approach.J Neural Transm Suppl 59: 213\u2013222, 2000.","journal-title":"J Neural Transm Suppl"},{"key":"10200213_CR13","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1111\/j.1471-4159.1993.tb09823.x","volume":"61","author":"M Vandermeeren","year":"1993","unstructured":"Vandermeeren M, Mercken M, Vanmechelen E, Six J, van de Voorde A, Martin JJ et al. Detection of t proteins in normal and Alzheimer\u2019s disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay.J Neurochem 61: 1828\u20131834, 1993.","journal-title":"J Neurochem"},{"key":"10200213_CR14","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/BF02815140","volume":"26","author":"K Blennow","year":"1995","unstructured":"Blennow K, Wallin A, \u00c5gren H, Spenger C, Siegfried J, Vanmechelen E. Tau protein in cerebrospinal fluid: a biochemical diagnostic marker for axonal degeneration in Alzheimer\u2019s disease?Mol Chem Neuropathol 26: 231\u2013245, 1995.","journal-title":"Mol Chem Neuropathol"},{"key":"10200213_CR15","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1212\/WNL.45.4.788","volume":"45","author":"C Vigo-Pelfrey","year":"1995","unstructured":"Vigo-Pelfrey C, Seubert P, Barbour R, Blomquist C, Lee M, Lee D et al. Elevation of microtubule-associated protein tau in the cerebrospinal fluid of patients with Alzheimer\u2019s disease.Neurology 45: 788\u2013793, 1995.","journal-title":"Neurology"},{"key":"10200213_CR16","first-page":"181","volume":"186","author":"H Mori","year":"1995","unstructured":"Mori H, Hosoda K, Matsubara E, Nakamoto T, Furiya Y, Endoh R et al. Tau in cerebrospinal fluids: establishment of the sandwich ELISA with antibody specific to the repeat sequence in tau.NeurosciLett 186: 181\u2013183, 1995.","journal-title":"NeurosciLett"},{"key":"10200213_CR17","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1385\/MN:24:1-3:087","volume":"24","author":"K Blennow","year":"2001","unstructured":"Blennow K, Vanmechelen E, Hampel H. CSF total tau, Ab42 and phosphorylated tau protein as biomarkers for Alzheimer\u2019s disease.Mol Neurobiol 24: 87\u201397, 2001.","journal-title":"Mol Neurobiol"},{"key":"10200213_CR18","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3233\/JAD-2000-23-402","volume":"2","author":"C Hesse","year":"2000","unstructured":"Hesse C, Rosengren L, Vanmechelen E, Vanderstichele H, Jensen C, Davidsson P et al. Cerebrospinal fluid markers for Alzheimer\u2019s disease evaluated after acute ischemic stroke.J Alzheimers Dis 2: 199\u2013206, 2000.","journal-title":"J Alzheimers Dis"},{"key":"10200213_CR19","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S0304-3940(97)00215-2","volume":"225","author":"M Otto","year":"1997","unstructured":"Otto M, Wiltfang J, Tumani H, Zerr I, Lantsch M, Kornhuber J et al. Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease.Neurosci Lett 225: 210\u2013212, 1997.","journal-title":"Neurosci Lett"},{"key":"10200213_CR20","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1212\/WNL.53.7.1488","volume":"53","author":"N Andreasen","year":"1999","unstructured":"Andreasen N, Minthon L, Clarberg A, Davidsson P, Gottfries J, Vanmechelen E et al. Sensitivity, specificity and stability of CSF t-tau in AD in a community-based patient sample.Neurology 53: 1488\u20131494, 1999.","journal-title":"Neurology"},{"key":"10200213_CR21","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0304-3940(00)01036-3","volume":"285","author":"E Vanmechelen","year":"2000","unstructured":"Vanmechelen E, Vanderstichele H, Davidsson P, Van Kerschaver E, Van Der Perre B, Sjogren M et al. Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization.Neurosci Lett 285: 49\u201352, 2000.","journal-title":"Neurosci Lett"},{"key":"10200213_CR22","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0304-3940(99)00476-0","volume":"270","author":"K Ishiguro","year":"1999","unstructured":"Ishiguro K, Ohno H, Arai H, Yamaguchi H, Urakami K, Park JM et al. Phosphorylated tau in human cerebrospinal fluid is a diagnostic marker for Alzheimer\u2019s disease.Neurosci Lett 270: 91\u201394, 1999.","journal-title":"Neurosci Lett"},{"key":"10200213_CR23","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0304-3940(00)01178-2","volume":"287","author":"R Kohnken","year":"2000","unstructured":"Kohnken R, Buerger K, Zinkowski R, Miller C, Kerkman D, DeBernardis J et al. Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer\u2019s disease patients.Neurosci Lett 287: 187\u2013190, 2000.","journal-title":"Neurosci Lett"},{"key":"10200213_CR24","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/S0002-9440(10)62554-0","volume":"160","author":"YY Hu","year":"2002","unstructured":"Hu YY, He SS, Wang X, Duan QH, Grundke-Iqbal I, Iqbal K et al. Levels of nonphosphorylated and phosphorylated tau in cerebrospinal fluid of Alzheimer\u2019s disease patients: an ultrasensitive bienzyme-substrate-recycle enzyme-linked immunosorbent assay.Am J Pathol 160: 1269\u20131278, 2002.","journal-title":"Am J Pathol"},{"key":"10200213_CR25","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0304-3940(00)01697-9","volume":"297","author":"C Hesse","year":"2001","unstructured":"Hesse C, Rosengren L, Andreasen N, Davidsson P, Vanderstichele H, Vanmechelen E et al. Transient increase in CSF total tau but not phospho-tau after acute stroke.Neurosci Lett 297: 187\u2013190, 2001.","journal-title":"Neurosci Lett"},{"key":"10200213_CR26","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/sj.mp.4001220","volume":"8","author":"M Riemenschneider","year":"2003","unstructured":"Riemenschneider M, Wagenpfeil S, Vanderstichele H, Otto M, Wiltfang J, Kretzschmar H et al. Phospho-tau\/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt-Jakob disease from other dementias.Mol Psychiatry 8: 343\u2013347, 2003.","journal-title":"Mol Psychiatry"},{"key":"10200213_CR27","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1073\/pnas.82.12.4245","volume":"82","author":"CL Masters","year":"1985","unstructured":"Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K. Amyloid plaque core protein in Alzheimer\u2019s disease and Down syndrome.Proc Natl Acad Sci USA 82: 4245\u20134249, 1985.","journal-title":"Proc Natl Acad Sci USA"},{"key":"10200213_CR28","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/0092-8674(93)90312-E","volume":"75","author":"C Haas","year":"1993","unstructured":"Haas C, Selkoe DJ. Cellular processing of \u03b2-amyloid precursor protein and the genesis of amyloid \u03b2-peptide.Cell 75: 1039\u20131042, 1993.","journal-title":"Cell"},{"key":"10200213_CR29","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/325733a0","volume":"325","author":"J Kang","year":"1987","unstructured":"Kang J, Lemaire HG, Unterbeck A, Salbaum JM, Masters CL, Grzeschik KH et al. The precursor of Alzheimer\u2019s disease amyloid A4 protein resembles a cell-surface receptor.Nature 325: 733\u2013736, 1987.","journal-title":"Nature"},{"key":"10200213_CR30","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/359325a0","volume":"359","author":"P Seubert","year":"1992","unstructured":"Seubert P, Vigo-Pelfrey C, Esch F, Lee M, Dovey H, Davis D et al. Isolation and quantification of soluble Alzheimer\u2019s \u03b2-peptide from biological fluids.Nature 359: 325\u2013327, 1992.","journal-title":"Nature"},{"key":"10200213_CR31","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1073\/pnas.89.7.2551","volume":"89","author":"WE Nostrand Van","year":"1992","unstructured":"Van Nostrand WE, Wagner SL, Shankle WR, Farrow JS, Dick M, Rozemuller JM et al. Decreased levels of soluble amyloid \u03b2-protein precursor in cerebrospinal fluid of live Alzheimer disease patients.Proc Natl Acad Sci USA 89: 2551\u20132555, 1992.","journal-title":"Proc Natl Acad Sci USA"},{"key":"10200213_CR32","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/0140-6736(92)91771-Y","volume":"340","author":"M Farlow","year":"1992","unstructured":"Farlow M, Ghetti B, Benson MD, Farrow JS, van Nostrand WE, Wagner SL. Low cerebrospinal-fluid concentrations of soluble amyloid \u03b2-protein precursor in hereditary Alzheimer\u2019s disease.Lancet 340: 453\u2013454, 1992.","journal-title":"Lancet"},{"key":"10200213_CR33","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1006\/bbrc.1994.1634","volume":"200","author":"M Tabaton","year":"1994","unstructured":"Tabaton M, Nunzi MG, Xue R, Usiak M, Autilio-Gambetti L, Gambetti P. Soluble amyloid \u03b2-protein is a marker of Alzheimer amyloid in brain but not in cerebrospinal fluid.Biochem Biophys Res Commun 200: 1598\u20131603, 1994.","journal-title":"Biochem Biophys Res Commun"},{"key":"10200213_CR34","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/ana.410370221","volume":"37","author":"WA Gool van","year":"1995","unstructured":"van Gool WA, Kuiper MA, Walstra GJ, Wolters EC, Bolhuis PA. Concentrations of amyloid \u03b2-protein in cerebrospinal fluid of patients with Alzheimer\u2019s disease.Ann Neurol 37: 277\u2013279, 1995.","journal-title":"Ann Neurol"},{"key":"10200213_CR35","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/ana.410380413","volume":"38","author":"R Motter","year":"1995","unstructured":"Motter R, Vigo-Pelfrey C, Kholodenko D, Barbour R, Johnson-Wood K, Galasko D et al. Reduction of \u03b2-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer\u2019s disease.Ann Neurol 38: 643\u2013648, 1995.","journal-title":"Ann Neurol"},{"key":"10200213_CR36","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1046\/j.1471-4159.1996.66010259.x","volume":"66","author":"PC Southwick","year":"1996","unstructured":"Southwick PC, Yamagata SK, Echols CL, Higson GJ, Neynaber SA, Parson RE et al. Assessment of amyloid \u03b2-protein in cerebrospinal fluid as an aid in the diagnosis of Alzheimer\u2019s disease.J Neurochem 66: 259\u2013265, 1996.","journal-title":"J Neurochem"},{"key":"10200213_CR37","doi-asserted-by":"crossref","first-page":"4693","DOI":"10.1021\/bi00069a001","volume":"32","author":"JT Jarrett","year":"1993","unstructured":"Jarrett JT, Berger EP, Lansbury PT. The carboxy terminus of the \u03b2-amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer\u2019s disease.Biochemistry 32: 4693\u20134697, 1993.","journal-title":"Biochemistry"},{"key":"10200213_CR38","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/0896-6273(94)90458-8","volume":"13","author":"T Iwatsubo","year":"1994","unstructured":"Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y. Visualization of A\u03b242(43) and A\u03b240 in senile plaques with end-specific A\u03b2 monoclonals: evidence that an initially deposited species is A\u03b242(43).Neuron 13: 45\u201353, 1994.","journal-title":"Neuron"},{"key":"10200213_CR39","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1006\/bbrc.1994.2740","volume":"205","author":"A Tamaoka","year":"1994","unstructured":"Tamaoka A, Kondo T, Odaka A, Sahara N, Sawamura N, Ozawa K et al. Biochemical evidence for the long-tail form (A\u03b2 1\u201342\/43) of amyloid \u03b2 protein as a seed molecule cerebral deposits of Alzheimer\u2019s disease.Biochem Biophys Res Commun 205: 834\u2013842, 1994.","journal-title":"Biochem Biophys Res Commun"},{"key":"10200213_CR40","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1006\/abbi.1993.1112","volume":"301","author":"DL Miller","year":"1993","unstructured":"Miller DL, Papayannopoulos IA, Styles J, Bobin SA, Lin YY, Biemann K, Iqbal K. Peptide composition of the cerebrovascular and senile plaque core amyloid deposits of Alzheimer\u2019s disease.Arch Biochem Biophys 301: 41\u201352, 1993.","journal-title":"Arch Biochem Biophys"},{"key":"10200213_CR41","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/978-1-4615-5337-3_110","volume-title":"Progress in Alzheimer\u2019s and Parkinson\u2019s diseases","author":"H Vanderstichele","year":"1998","unstructured":"Vanderstichele H, Blennow K, D\u2019Heuvaert ND, Buyse MA, Wallin A, Andreasen N et al. Development of a specific diagnostic test for measurement of \u03b2-amyloid(1\u201342) in CSF. In:Progress in Alzheimer\u2019s and Parkinson\u2019s diseases (Fisher A, Hanin I, Yoshida M, eds), pp 773\u2013778. New York: Plenum, 1998."},{"key":"10200213_CR42","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1001\/archneur.57.1.100","volume":"57","author":"PD Mehta","year":"2000","unstructured":"Mehta PD, Pirttila T, Mehta SP, Sersen EA, Aisen PS, Wisniewski HM. Plasma and cerebrospinal fluid levels of amyloid \u03b2 proteins 1\u201340 and 1\u201342 in Alzheimer disease.Arch Neurol 57: 100\u2013105, 2000.","journal-title":"Arch Neurol"},{"key":"10200213_CR43","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1001\/jama.289.16.2094","volume":"289","author":"T Sunderland","year":"2003","unstructured":"Sunderland T, Linker G, Mirza N, Putnam KT, Friedman DL, Kimmel LH et al. Decreased \u03b2-amyloidl-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease.JAMA 289: 2094\u20132103, 2003.","journal-title":"JAMA"},{"key":"10200213_CR44","doi-asserted-by":"crossref","first-page":"22908","DOI":"10.1074\/jbc.271.37.22908","volume":"271","author":"N Ida","year":"1996","unstructured":"Ida N, Hartmann T, Pantel J, Schroder J, Zerfass R, Forstl H et al. Analysis of heterogeneous A4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive Western blot assay.J Biol Chem 271: 22908\u201322914, 1996.","journal-title":"J Biol Chem"},{"key":"10200213_CR45","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/sj.mp.4000313","volume":"2","author":"J Schroder","year":"1997","unstructured":"Schroder J, Pantel J, Ida N, Essig M, Hartmann T, Knopp MV et al. Cerebral changes and cerebrospinal fluid \u03b2-amyloid in Alzheimer\u2019s disease: a study with quantitative magnetic resonance imaging.Mol Psychiatry 2: 505\u2013507, 1997.","journal-title":"Mol Psychiatry"},{"key":"10200213_CR46","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1002\/1531-8249(199904)45:4<504::AID-ANA12>3.0.CO;2-9","volume":"45","author":"M Jensen","year":"1999","unstructured":"Jensen M, Schroder J, Blomberg M, Engvall B, Pantel J, Ida N et al. Cerebrospinal fluid A \u03b242 is increased early in sporadic Alzheimer\u2019s disease and declines with disease progression.Ann Neurol 45: 504\u2013511, 1999.","journal-title":"Ann Neurol"},{"key":"10200213_CR47","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1046\/j.1471-4159.2002.00818.x","volume":"81","author":"J Wiltfang","year":"2002","unstructured":"Wiltfang J, Esselmann H, Bibl M, Smirnov A, Otto M, Paul S et al. Highly conserved and disease-specific patterns of carboxyterminally truncated A\u03b2 peptides 1\u201337\/38\/39 in addition to 1\u201340\/42 in Alzheimer\u2019s disease and in patients with chronic neuroinflammation.J Neurochem 81: 481\u2013496, 2002.","journal-title":"J Neurochem"},{"key":"10200213_CR48","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1002\/rcm.1048","volume":"17","author":"P Lewczuk","year":"2003","unstructured":"Lewczuk P, Esselmann H, Meyer M, Wollscheid V, Neumann M, Otto M et al. The amyloid-\u03b2 (A\u03b2) peptide pattern in cerebrospinal fluid in Alzheimer\u2019s disease: evidence of a novel carboxyterminally elongated A\u03b2 peptide.Rapid Commun Mass Spectrom 17: 1291\u20131296, 2003.","journal-title":"Rapid Commun Mass Spectrom"},{"key":"10200213_CR49","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1001\/archneur.56.6.673","volume":"56","author":"N Andreasen","year":"1999","unstructured":"Andreasen N, Hesse C, Davidsson P, Wallin A, Minthon L, Winblad B et al. Cerebrospinal fluid \u03b2-amyloid(1\u201342) in Alzheimer\u2019s disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease.Arch Neurol 56: 673\u2013680, 1999.","journal-title":"Arch Neurol"},{"key":"10200213_CR50","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s007020070079","volume":"107","author":"M Sj\u00f6gren","year":"2000","unstructured":"Sj\u00f6gren M, Minthon L, Davidsson P, Gran\u00e9rus AK, Clarberg A, Vanderstichele H et al. CSF levels of tau, \u03b2-amyloidl-42 and GAP-43 in frontotemporal dementia, other types of dementia and normal aging.J Neural Transm 107: 563\u2013579, 2000.","journal-title":"J Neural Transm"},{"key":"10200213_CR51","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1212\/WNL.54.5.1099","volume":"54","author":"M Otto","year":"2000","unstructured":"Otto M, Esselmann H, Schulz-Shaeffer W, Neumann M, Schroter A, Ratzka P et al. Decreased \u03b2-amyloidl-42 in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease.Neurology 54: 1099\u20131102, 2000.","journal-title":"Neurology"},{"key":"10200213_CR52","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1159\/000048642","volume":"13","author":"M Sj\u00f6gren","year":"2002","unstructured":"Sj\u00f6gren M, Davidsson P, Wallin A, Granerus AK, Grundstr\u00f6m E, Askmark H et al. Decreased CSF \u03b2-amyloid42 in Alzheimer\u2019s disease and amyotrophic lateral sclerosis may reflect mismetabolism of \u03b2-amyloid induced by separate mechanisms.Dement Geriatr Cogn Disord 13: 112\u2013118, 2002.","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10200213_CR53","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/mds.10321","volume":"18","author":"B Holmberg","year":"2003","unstructured":"Holmberg B, Johnels B, Blennow K, Rosengren L. Cerebrospinal fluid A\u03b242 is reduced in multiple system atrophy but normal in Parkinson\u2019s disease and progressive supranuclear palsy.Mov Disord 18: 186\u2013190, 2003.","journal-title":"Mov Disord"},{"key":"10200213_CR54","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1212\/01.WNL.0000046581.81650.D0","volume":"60","author":"D Strozyk","year":"2003","unstructured":"Strozyk D, Blennow K, White LR, Launer LJ. CSF A\u03b242 levels correlate with amyloid-neuropathology in a population-based autopsy study.Neurology 60: 652\u2013656, 2003.","journal-title":"Neurology"},{"key":"10200213_CR55","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0022-510X(96)00314-0","volume":"148","author":"A Tamaoka","year":"1997","unstructured":"Tamaoka A, Sawamura N, Fukushima T, Shoji S, Matsubara E, Shoji M et al. Amyloid \u03b2 protein 42(43) in cerebrospinal fluid of patients with Alzheimer\u2019s disease.J Neurol Sci 148: 41\u201345, 1997.","journal-title":"J Neurol Sci"},{"key":"10200213_CR56","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/ana.410440108","volume":"44","author":"M Kanai","year":"1998","unstructured":"Kanai M, Matsubara E, Isoe K, Urakami K, Nakashima K, Arai H et al. Longitudinal study of cerebrospinal fluid levels of tau, A \u03b21\u201340, and A \u03b2 1\u201342(43) in Alzheimer\u2019s disease: a study in Japan.Ann Neurol 44: 17\u201326, 1998.","journal-title":"Ann Neurol"},{"key":"10200213_CR57","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S0022-510X(98)00122-1","volume":"158","author":"M Shoji","year":"1998","unstructured":"Shoji M, Matsubara E, Kanai M, Watanabe M, Nakamura T, Tomidokoro Y et al. Combination assay of CSF tau, A\u03b2 1\u201340 and A\u03b2 1\u201342(43) as a biochemical marker of Alzheimer\u2019s disease.J Neurol Sci 158: 134\u2013140, 1998.","journal-title":"J Neurol Sci"},{"key":"10200213_CR58","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1159\/000008156","volume":"43","author":"R Fukuyama","year":"2000","unstructured":"Fukuyama R, Mizuno T, Mori S, Nakajima K, Fushiki S, Yanagisawa K. Age-dependent change in the levels of A\u03b240 and A\u03b242 in cerebrospinal fluid from control subjects, and a decrease in the ratio of A\u03b242 to A\u03b240 level in cerebrospinal fluid from Alzheimer\u2019s disease patients.Eur Neurol 43: 155\u2013160, 2000.","journal-title":"Eur Neurol"},{"key":"10200213_CR59","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1111\/j.1471-4159.1993.tb09841.x","volume":"61","author":"C Vigo-Pelfrey","year":"1993","unstructured":"Vigo-Pelfrey C, Lee D, Keim P, Lieberburg I, Schenk DB. Characterization of \u03b2-amyloid peptide from human cerebrospinal fluid.J Neurochem 61: 1965\u20131968, 1993.","journal-title":"J Neurochem"},{"key":"10200213_CR60","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1046\/j.1471-4159.2003.01818.x","volume":"85","author":"N Sergeant","year":"2003","unstructured":"Sergeant N, Bombois S, Ghestem A, Drobecq H, Kostanjevecki V, Missiaen C et al. Truncated \u03b2-amyloid peptide species in pre-clinical Alzheimer\u2019s disease as new targets for the vaccination approach.J Neurochem 85: 1581\u20131591, 2003.","journal-title":"J Neurochem"},{"key":"10200213_CR61","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S1474-4422(03)00530-1","volume":"2","author":"K Blennow","year":"2003","unstructured":"Blennow K, Hampel H. CSF markers for incipient Alzheimer\u2019s disease.Lancet Neurol 2: 605\u2013613, 2003.","journal-title":"Lancet Neurol"},{"key":"10200213_CR62","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1002\/ana.410380414","volume":"38","author":"H Arai","year":"1995","unstructured":"Arai H, Terajima M, Miura M, Higuchi S, Muramatsu T, Machida N et al. Tau in cerebrospinal fluid: a potential diagnostic marker in Alzheimer\u2019s disease.Ann Neurol 38: 649\u2013652, 1995.","journal-title":"Ann Neurol"},{"key":"10200213_CR63","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1136\/jnnp.64.3.298","volume":"64","author":"N Andreasen","year":"1998","unstructured":"Andreasen N, Vanmechelen E, Van de Voorde A, Davidsson P, Hesse C, Tarvonen S, R\u00e4ih\u00e4 I, Sourander L, Winblad B, Blennow K. Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer\u2019s disease: a community-based follow-up study.J Neurol Neurosurg Psychiatry 64: 298\u2013305, 1998.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10200213_CR64","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/S0304-3940(98)00781-2","volume":"256","author":"H Arai","year":"1998","unstructured":"Arai H, Satoh-Nakagawa T, Higuchi M, Morikawa Y, Miura M, Kawakami H, Seki H, Takase S, Sasaki H. No increase in cerebrospinal fluid tau protein levels in patients with vascular dementia.Neurosci Lett 256: 174\u2013176, 1998.","journal-title":"Neurosci Lett"},{"key":"10200213_CR65","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1097\/00002093-199812000-00020","volume":"12","author":"A Kurz","year":"1998","unstructured":"Kurz A, Riemenschneider M, Buch K, Willoch F, Bartenstein P, Muller U et al. Tau protein in cerebrospinal fluid is significantly increased at the earliest stage of Alzheimer disease.Alzheimer Dis Assoc Disord 12: 372\u2013377, 1998.","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"10200213_CR66","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1358\/mf.1998.20.3.485673","volume":"20","author":"T Nishimura","year":"1998","unstructured":"Nishimura T, Takeda M, Nakamura Y, Yosbida Y, Arai H, Sasaki H et al. Basic and clinical studies on the measurement of tau protein in cerebrospinal fluid as a biological marker for Alzheimer\u2019s disease and related disorders: multicenter study in Japan.Methods Find Exp Clin Pharmacol 20: 227\u2013235, 1998.","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"10200213_CR67","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1212\/WNL.52.8.1555","volume":"52","author":"F Hulstaert","year":"1999","unstructured":"Hulstaert F, Blennow K, Ivanoiu A, Schoonderwaldt HC, Riemenschneider M, De Deyn PP et al. Improved discrimination of AD patients using \u03b2-amyloid(l\u201342) and tau levels in CSF.Neurology 52: 1555\u20131562, 1999.","journal-title":"Neurology"},{"key":"10200213_CR68","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1006\/exnr.2001.7814","volume":"172","author":"M Maruyama","year":"2001","unstructured":"Maruyama M, Arai H, Sugita M, Tanji H, Higuchi M, Okamura N et al. Cerebrospinal fluid amyloid \u03b2(l\u201342) levels in the mild cognitive impairment stage of Alzheimer\u2019s disease.Exp Neurol 172: 433\u2013436, 2001.","journal-title":"Exp Neurol"},{"key":"10200213_CR69","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1159\/000051268","volume":"12","author":"M Sj\u00f6gren","year":"2001","unstructured":"Sj\u00f6gren M, Davidsson P, Gottfries J, Vanderstichele H, Edman A, Vanmechelen E et al. The cerebrospinal fluid levels of tau, growth-associated protein-43 and soluble amyloid precursor protein correlate in Alzheimer\u2019s disease, reflecting a common patho-physiological process.Dement Geriatr Cogn Disord 12: 257\u2013264, 2001.","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10200213_CR70","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1136\/jnnp.70.5.624","volume":"70","author":"M Sj\u00f6gren","year":"2001","unstructured":"Sj\u00f6gren M, Davidsson P, Tullberg M, Minthon L, Wallin A, Wikkels\u00f6 C et al. Both total and hyperphosphorylated tau are increased in Alzheimer\u2019s disease.J Neurol Neurosurg Psychiatry 70: 624\u2013630, 2001.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10200213_CR71","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1001\/archneur.59.8.1267","volume":"59","author":"K Buerger","year":"2002","unstructured":"Buerger K, Zinkowski R, Teipel SJ, Tapiola T, Arai H, Blennow K et al. Differential diagnosis of Alzheimer\u2019s disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231.Arch Neurol 59: 1267\u20131272, 2002.","journal-title":"Arch Neurol"},{"key":"10200213_CR72","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1212\/WNL.58.11.1622","volume":"58","author":"M Riemenschneider","year":"2002","unstructured":"Riemenschneider M, Wagenpfeil S, Diehl J, Lautenschlager N, Theml T, Heldmann B et al. Tau and A\u03b242 protein in CSF of patients with frontotemporal degeneration.Neurology 58: 1622\u20131628, 2002.","journal-title":"Neurology"},{"key":"10200213_CR73","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S0197-4580(01)00309-8","volume":"23","author":"M Shoji","year":"2002","unstructured":"Shoji M, Matsubara E, Murakami T, Manabe Y, Abe K, Kanai M et al. Cerebrospinal fluid tau in dementia disorders: a large scale multicenter study by a Japanese study group.Neurobiol Aging 23: 363\u2013370, 2002.","journal-title":"Neurobiol Aging"},{"key":"10200213_CR74","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1046\/j.1468-1331.2003.00562.x","volume":"10","author":"E Kapaki","year":"2003","unstructured":"Kapaki E, Paraskevas GP, Zalonis I, Zournas C. CSF tau protein and \u03b2-amyloid (1\u201342) in Alzheimer\u2019s disease diagnosis: discrimination from normal ageing and other dementias in the Greek population.Eur J Neurol 10: 119\u2013128, 2003.","journal-title":"Eur J Neurol"},{"key":"10200213_CR75","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1159\/000072803","volume":"16","author":"A Wallin","year":"2003","unstructured":"Wallin A, Sj\u00f6gren M, Davidsson P, Blennow K. Decreased cerebrospinal fluid acetylcholinesterase in patients with subcortical ischemic vascular dementia.Dement Geriatr Cogn Disord 16: 200\u2013207, 2003.","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10200213_CR76","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1136\/jnnp.71.3.401","volume":"71","author":"E Kapaki","year":"2001","unstructured":"Kapaki E, Kilidireas K, Paraskevas GP, Michalopoulou M, Patsouris E. Highly increased CSF tau protein and decreased \u03b2-amyloid (1\u201342) in sporadic CJD: a discrimination from Alzheimer\u2019s disease?J Neurol Neurosurg Psychiatry 71: 401\u2013403, 2001.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10200213_CR77","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1212\/WNL.58.2.192","volume":"58","author":"M Otto","year":"2002","unstructured":"Otto M, Wiltfang J, Cepek L, Neumann M, Mollenhauer B, Steinacker P et al. Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt-Jakob disease.Neurology 58: 192\u2013197, 2002.","journal-title":"Neurology"},{"key":"10200213_CR78","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/jnnp.73.1.79","volume":"73","author":"B Everbroeck Van","year":"2002","unstructured":"Van Everbroeck B, Green AJ, Vanmechelen E, Vanderstichele H, Pals P, Sanchez-Valle R et al. Phosphorylated tau in cerebrospinal fluid as a marker for Creutzfeldt-Jakob disease.J Neurol Neurosurg Psychiatry 73: 79\u201381, 2002.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10200213_CR79","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1042\/bst0300382","volume":"30","author":"AJ Green","year":"2002","unstructured":"Green AJ. Use of 14-3-3 in the diagnosis of Creutzfeldt-Jakob disease.Biochem Soc Trans 30: 382\u2013386, 2002.","journal-title":"Biochem Soc Trans"},{"key":"10200213_CR80","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s004010050418","volume":"91","author":"KA Jellinger","year":"1996","unstructured":"Jellinger KA. Diagnostic accuracy of Alzheimer\u2019s disease: a clinicopathological study.Acta Neuropathol 91: 219\u2013220, 1996.","journal-title":"Acta Neuropathol"},{"key":"10200213_CR81","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s004010050412","volume":"91","author":"O Kosunen","year":"1996","unstructured":"Kosunen O, Soininen H, Palj\u00e4rvi L, Heinonen O, Talasniemi S, Riekkinen PJ Sr. Diagnostic accuracy of Alzheimer\u2019s disease: a neuropathological study.Acta Neuropathol 91: 185\u2013193, 1996.","journal-title":"Acta Neuropathol"},{"key":"10200213_CR82","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/j.1479-8301.2001.tb00073.x","volume":"1","author":"M Takeda","year":"2001","unstructured":"Takeda M, Tanaka T, Arai H, Sasaki H, Shoji M, Okamoto K. Basic and clinical studies on the measurement of \u03b2-amyloid(l\u201342) in cerebrospinal fluid as a diagnostic marker for Alzheimer\u2019s disease and related disorders: multicenter study in Japan.Psychogeriatrics 1: 56\u201363, 2001.","journal-title":"Psychogeriatrics"},{"key":"10200213_CR83","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1006\/bbrc.1997.6908","volume":"236","author":"H Arai","year":"1997","unstructured":"Arai H, Morikawa Y, Higuchi M, Matsui T, Clark CM, Miura M et al. Cerebrospinal fluid tau levels in neurodegenerative diseases with distinct tau-related pathology.Biochem Biophys Res Commun 236: 262\u2013264, 1997.","journal-title":"Biochem Biophys Res Commun"},{"key":"10200213_CR84","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/00002093-199809000-00015","volume":"12","author":"P Mecocci","year":"1998","unstructured":"Mecocci P, Cherubini A, Bregnocchi M, Chionne F, Cecchetti R, Lowenthal DT et al. Tau protein in cerebrospinal fluid: a new diagnostic and prognostic marker in Alzheimer disease?Alzheimer Dis Assoc Disord 12: 211\u2013214, 1998.","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"10200213_CR85","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.1097\/00001756-199911260-00005","volume":"10","author":"L Molina","year":"1999","unstructured":"Molina L, Touchon J, Herpe M, Lefranc D, Duplan L, Cristol JP et al. Tau and apo E in CSF: potential aid for discriminating Alzheimer\u2019s disease from other dementias.NeuroReport 10: 3491\u20133495, 1999.","journal-title":"NeuroReport"},{"key":"10200213_CR86","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/ana.1054","volume":"50","author":"N Itoh","year":"2001","unstructured":"Itoh N, Arai H, Urakami K, Ishiguro K, Ohno H, Hampel H et al. Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer\u2019s disease.Ann Neurol 50: 150\u2013156, 2001.","journal-title":"Ann Neurol"},{"key":"10200213_CR87","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1001\/archneur.60.9.1218","volume":"60","author":"E Gomez-Tortosa","year":"2003","unstructured":"Gomez-Tortosa E, Gonzalo I, Fanjul S, Sainz MJ, Cantarero S, Cemillan C et al. Cerebrospinal fluid markers in dementia with Lewy bodies compared with Alzheimer disease.Arch Neurol 60: 1218\u20131222, 2003.","journal-title":"Arch Neurol"},{"key":"10200213_CR88","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1212\/WNL.54.7.1498","volume":"54","author":"PJ Kahle","year":"2000","unstructured":"Kahle PJ, Jakowec M, Teipel SJ, Hampel H, Petzinger GM, Di Monte DA et al. Combined assessment of tau and neuronal thread protein in Alzheimer\u2019s disease CSF.Neurology 54: 1498\u20131504, 2000.","journal-title":"Neurology"},{"key":"10200213_CR89","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1212\/WNL.54.9.1875","volume":"54","author":"K Kanemaru","year":"2000","unstructured":"Kanemaru K, Kameda N, Yamanouchi H. Decreased CSF amyloid \u03b242 and normal tau levels in dementia with Lewy bodies.Neurology 54: 1875\u20131876, 2000.","journal-title":"Neurology"},{"key":"10200213_CR90","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1002\/jnr.10599","volume":"72","author":"J S\u00e1ez-Valero","year":"2003","unstructured":"S\u00e1ez-Valero J, Fodero LR, Sj\u00f6gren M, Andreasen N, Amici S, Gallai V et al. Glycosylation of acetylcholinesterase and butyryl-cholinesterase changes as a function of the duration of Alzheimer\u2019s disease.J Neurosci Res 72: 520\u2013526, 2003.","journal-title":"J Neurosci Res"},{"key":"10200213_CR91","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/j.1530-0277.1999.tb04156.x","volume":"23","author":"Y Morikawa","year":"1999","unstructured":"Morikawa Y, Arai H, Matsushita S, Kato M, Higuchi S, Miura M et al. Cerebrospinal fluid tau protein levels in demented and nondemented alcoholics.Alcohol Clin Exp Res 23: 575\u2013577, 1999.","journal-title":"Alcohol Clin Exp Res"},{"key":"10200213_CR92","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s100720170055","volume":"22","author":"L Parnetti","year":"2001","unstructured":"Parnetti L, Lanari A, Amici S, Gallai V, Vanmechelen E, Hulstaert F. CSF phosphorylated tau is a possible marker for discriminating Alzheimer\u2019s disease from dementia with Lewy bodies. Phospho-tau International Study Group.Neurol Sci 22: 77\u201378, 2001.","journal-title":"Neurol Sci"},{"key":"10200213_CR93","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1001\/archpsyc.61.1.95","volume":"61","author":"H Hampel","year":"2004","unstructured":"Hampel H, Buerger K, Zinkowski R, Teipel SJ, Andreasen N, Sj\u00f6gren M et al. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer\u2019s disease \u2014 a comparative study.Arch Gen Psychiatry 61: 95\u2013102, 2004.","journal-title":"Arch Gen Psychiatry"},{"key":"10200213_CR94","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1001\/archneur.60.9.1202","volume":"60","author":"A Maddalena","year":"2003","unstructured":"Maddalena A, Papassotiropoulos A, Muller-Tillmanns B, Jung HH, Hegi T, Nitsch RM et al. Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to \u03b2-amyloid peptide42.Arch Neurol 60: 1202\u20131206, 2003.","journal-title":"Arch Neurol"},{"key":"10200213_CR95","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1001\/archneur.60.9.1209","volume":"60","author":"SM Rosso","year":"2003","unstructured":"Rosso SM, van Herpen E, Pijnenburg YA, Schoonenboom NS, Scheltens P, Heutink P et al. Total tau and phosphorylated tau 181 levels in the cerebrospinal fluid of patients with frontotemporal dementia due to P301L and G272V tau mutations.Arch Neurol 60: 1209\u20131213, 2003.","journal-title":"Arch Neurol"},{"key":"10200213_CR96","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1176\/appi.ajp.160.2.376","volume":"160","author":"K Buerger","year":"2003","unstructured":"Buerger K, Zinkowski R, Teipel SJ, Arai H, DeBernardis J, Kerkman D et al. Differentiation of geriatric major depression from Alzheimer\u2019s disease with CSF tau protein phosphorylated at threonine 231.Am J Psychiatry 160: 376\u2013379, 2003.","journal-title":"Am J Psychiatry"},{"key":"10200213_CR97","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s007020170091","volume":"108","author":"N Rosler","year":"2001","unstructured":"Rosler N, Wichart I, Jellinger KA. Clinical significance of neurobiochemical profiles in the lumbar cerebrospinal fluid of Alzheimer\u2019s disease patients.J Neural Transm 108: 231\u2013246, 2001.","journal-title":"J Neural Transm"},{"key":"10200213_CR98","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s007020200031","volume":"109","author":"C Briani","year":"2002","unstructured":"Briani C, Ruggero S, Naccarato M, Cagnin A, Ricchieri GL, Pasqui L et al. Combined analysis of CSF \u03b2A42 peptide and tau protein and serum antibodies to glycosaminoglycans in Alzheimer\u2019s disease: preliminary data.J Neural Transm 109: 393\u2013398, 2002.","journal-title":"J Neural Transm"},{"key":"10200213_CR99","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1007\/s00702-002-0763-y","volume":"109","author":"C Mulder","year":"2002","unstructured":"Mulder C, Schoonenboom SN, Wahlund LO, Scheltens P, van Kamp GJ, Veerhuis R, Hack CE, Blomberg M, Schutgens RB, Eikelenboom P. CSF markers related to pathogenetic mechanisms in Alzheimer\u2019s disease.J Neural Transm 109: 1491\u20131498, 2002.","journal-title":"J Neural Transm"},{"key":"10200213_CR100","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0304-3940(99)00617-5","volume":"273","author":"N Andreasen","year":"1999","unstructured":"Andreasen N, Minthon L, Vanmechelen E, Vanderstichele H, Davidsson P, Winblad B et al. CSF t-tau and CSF-A\u03b242 as predictors of development of Alzheimer\u2019s disease in patients with mild cognitive impairment.Neurosci Lett 273: 5\u20138, 1999.","journal-title":"Neurosci Lett"},{"key":"10200213_CR101","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1001\/archneur.58.3.373","volume":"58","author":"N Andreasen","year":"2001","unstructured":"Andreasen N, Minthon L, Davidsson P, Vanmechelen E, Vanderstichele H, Winblad B. Evaluation of CSF-tau and CSF-A\u03b242 as diagnostic markers for Alzheimer\u2019s disease in clinical practice.Arch Neurol 58: 373\u2013379, 2001.","journal-title":"Arch Neurol"},{"key":"10200213_CR102","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/jnnp.71.4.557","volume":"71","author":"N Andreasen","year":"2001","unstructured":"Andreasen N, Gottfries J, Vanmechelen E, Vanderstichele H, Davidsson P, Winblad B, Rosengren L, Blennow K. Evaluation of CSF biomarkers for axonal and neuronal degeneration, gliosis, and \u03b2-amyloid metabolism in Alzheimer\u2019s disease.J Neurol Neurosurg Psychiatry 71: 557\u2013558, 2001.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10200213_CR103","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/0304-3940(96)12810-X","volume":"212","author":"M Riemenschneider","year":"1996","unstructured":"Riemenschneider M, Buch K, Schmolke M, Kurz A, Guder WG. Cerebrospinal protein tau is elevated in early Alzheimer\u2019s disease.Neurosci Lett 212: 209\u2013211, 1996.","journal-title":"Neurosci Lett"},{"key":"10200213_CR104","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1212\/WNL.48.3.632","volume":"48","author":"D Galasko","year":"1997","unstructured":"Galasko D, Clark C, Chang L, Miller B, Green RC, Motter R et al. Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer\u2019s disease.Neurology 48: 632\u2013635, 1997.","journal-title":"Neurology"},{"key":"10200213_CR105","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1001\/archneur.55.7.937","volume":"55","author":"D Galasko","year":"1998","unstructured":"Galasko D, Chang L, Motter R, Clark CM, Kaye J, Knopman D et al. High cerebrospinal fluid tau and low amyloid \u03b242 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype.Arch Neurol 55: 937\u2013945, 1998.","journal-title":"Arch Neurol"},{"key":"10200213_CR106","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1006\/exnr.2000.7501","volume":"166","author":"H Arai","year":"2000","unstructured":"Arai H, Ishiguro K, Ohno H, Moriyama M, Itoh N, Okamura N et al. CSF phosphorylated tau protein and mild cognitive impairment: a prospective study.Exp Neurol 166: 201\u2013203, 2000.","journal-title":"Exp Neurol"},{"key":"10200213_CR107","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1177\/089198870101400302","volume":"14","author":"J Gottfries","year":"2001","unstructured":"Gottfries J, Blennow K, Lehmann MW, Regland B, Gottfries CG. One-carbon metabolism and other biochemical correlate of cognitive impairment as visualized by principal component analysis.J Geriatr Psychiatry Neurol 14: 109\u2013114, 2001.","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"10200213_CR108","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1159\/000051284","volume":"12","author":"NT Lautenschlager","year":"2001","unstructured":"Lautenschlager NT, Riemenschneider M, Drzezga A. Primary degenerative mild cognitive impairment: study population, clinical, brain imaging and biochemical findings.Dement Geriatr Cogn Disord 12: 379\u2013386, 2001.","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10200213_CR109","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1001\/archneur.59.11.1729","volume":"59","author":"M Riemenschneider","year":"2002","unstructured":"Riemenschneider M, Lautenschlager N, Wagenpfeil S, Diehl J, Drzezga A, Kurz A. Cerebrospinal fluid tau and \u03b2-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment.Arch Neurol 59: 1729\u20131734, 2002.","journal-title":"Arch Neurol"},{"issue":"Suppl 179","key":"10200213_CR110","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1034\/j.1600-0404.107.s179.9.x","volume":"107","author":"N Andreasen","year":"2003","unstructured":"Andreasen N, Vanmechelen E, Vanderstichele H, Davidsson P, Blennow K. Cerebrospinal fluid levels of total-tau, phospho-tau and A\u03b242 predicts development of Alzheimer\u2019s disease in patients with mild cognitive impairment.Acta Neurol Scand 107(Suppl 179): 47\u201351, 2003","journal-title":"Acta Neurol Scand"},{"key":"10200213_CR111","first-page":"211","volume":"3","author":"H Arai","year":"1997","unstructured":"Arai H, Nakagawa T, Kosaka Y, Higuchi M, Matsui T, Okamura N et al. Elevated cerebrospinal fluid tau protein level as a predictor of dementia in memory-impaired patients.Alzheimer\u2019s Res 3: 211\u2013213, 1997.","journal-title":"Alzheimer\u2019s Res"},{"key":"10200213_CR112","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1212\/WNL.59.4.627","volume":"59","author":"K Buerger","year":"2002","unstructured":"Buerger K, Teipel SJ, Zinkowski R, Blennow K, Arai H, Engel R, Hofmann-Kiefer K et al. CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects.Neurology 59: 627\u2013629, 2002.","journal-title":"Neurology"},{"key":"10200213_CR113","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1159\/000068478","volume":"15","author":"I Skoog","year":"2003","unstructured":"Skoog I, Davidsson P, Aevarsson O, Vanderstichele H, Vanmechelen E, Blennow K. Cerebrospinal fluid \u03b2-amyloid 42 is reduced before the onset of sporadic dementia: a population-based study in 85-year-olds.Dement Geriatr Cogn Disord 15: 169\u2013176, 2003.","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10200213_CR114","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0968-0004(85)90108-2","volume":"10","author":"D Finley","year":"1985","unstructured":"Finley D, Varshavsky A. The ubiquitin system: functions and mechanisms.Trends Biochem Sci 10: 343\u2013347, 1985.","journal-title":"Trends Biochem Sci"},{"key":"10200213_CR115","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0079-6603(08)60019-7","volume":"33","author":"A Herschko","year":"1986","unstructured":"Herschko A, Ciechanover A. The ubiquitin pathway for the degradation of intracellular proteins.Prog Nucleic Acid Res Mol Biol 33: 19\u201356, 1986.","journal-title":"Prog Nucleic Acid Res Mol Biol"},{"key":"10200213_CR116","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/nbt0390-209","volume":"8","author":"BP Monia","year":"1990","unstructured":"Monia BP, Ecker DJ, Crooke ST. New perspectives on the structure and function of ubiquitin.Biotechnology 8: 209\u2013215, 1990.","journal-title":"Biotechnology"},{"key":"10200213_CR117","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1073\/pnas.84.9.3033","volume":"84","author":"G Perry","year":"1987","unstructured":"Perry G, Friedman R, Shaw G, Chau V. Ubiquitin is detected in neurofibrillary tangles and senile plaque neurites of Alzheimer disease brains.Proc Natl Acad Sci USA 84: 3033\u20133036, 1987.","journal-title":"Proc Natl Acad Sci USA"},{"key":"10200213_CR118","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1126\/science.3029875","volume":"235","author":"H Mori","year":"1987","unstructured":"Mori H, Kondo J, Ihara Y. Ubiquitin is a component of paired helical filaments in Alzheimer\u2019s disease.Science 235: 1641\u20131644, 1987.","journal-title":"Science"},{"key":"10200213_CR119","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/0006-8993(91)91692-T","volume":"566","author":"GP Wang","year":"1991","unstructured":"Wang GP, Khatoon S, Iqbal K, Grundke-Iqbal I. Brain ubiquitin is markedly elevated in Alzheimer disease.Brain Res 566: 146\u2013151, 1991.","journal-title":"Brain Res"},{"key":"10200213_CR120","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/BF00687608","volume":"62","author":"GP Wang","year":"1984","unstructured":"Wang GP, Grundke-Iqbal I, Kascsak RJ, Iqbal K, Wisniewski HM. Alzheimer neurofibrillary tangles: monoclonal antibodies to inherent antigen(s).Acta Neuropathol (Berl) 62: 268\u2013275, 1984.","journal-title":"Acta Neuropathol (Berl)"},{"key":"10200213_CR121","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0140-6736(85)90074-1","volume":"2","author":"PD Mehta","year":"1985","unstructured":"Mehta PD, Thal L, Wisniewski HM, Grundke-Iqbal I, Iqbal K. Paired helical filament antigen in CSF.Lancet 2: 35, 1985.","journal-title":"Lancet"},{"key":"10200213_CR122","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1111\/j.1471-4159.1989.tb09203.x","volume":"52","author":"G Perry","year":"1989","unstructured":"Perry G, Mulvihill P, Fried VA, Smith HT, Grundke-Iqbal I, Iqbal K. Immunochemical properties of ubiquitin conjugates in the paired helical filaments of Alzheimer disease.J Neurochem 52: 1523\u20131528, 1989.","journal-title":"J Neurochem"},{"key":"10200213_CR123","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/BF00310917","volume":"82","author":"GP Wang","year":"1991","unstructured":"Wang GP, Iqbal K, Bucht G, Winblad B, Wisniewski HM, Grundke-Iqbal I. Alzheimer\u2019s disease: paired helical filament immunoreactivity in cerebrospinal fluid.Acta Neuropathol (Berl) 82: 6\u201312, 1991.","journal-title":"Acta Neuropathol (Berl)"},{"key":"10200213_CR124","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0006-8993(94)91757-4","volume":"639","author":"T Kudo","year":"1994","unstructured":"Kudo T, Iqbal K, Ravid R, Swaab DF, Grundke-Iqbal I. Alzheimer disease: correlation of cerebrospinal fluid and brain ubiquitin levels.Brain Res 639: 1\u20137, 1994.","journal-title":"Brain Res"},{"key":"10200213_CR125","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1017\/S1041610294001584","volume":"6","author":"K Blennow","year":"1994","unstructured":"Blennow K, Davidsson P, Wallin A, Gottfries CG, Svennerholm L. Ubiquitin in cerebrospinal fluid in Alzheimer\u2019s disease and vascular dementia.Int Psychogeriatr 6: 13\u201322, 1994.","journal-title":"Int Psychogeriatr"},{"key":"10200213_CR126","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/ar.1091670402","volume":"167","author":"RL Friede","year":"1970","unstructured":"Friede RL, Samorajski T. Axon caliber related to neurofilaments and microtubules in sciatic nerve fibers of rats and mice.Anat Rec 167: 379\u2013387, 1970.","journal-title":"Anat Rec"},{"key":"10200213_CR127","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/jnr.1242","volume":"66","author":"M Sjogren","year":"2001","unstructured":"Sjogren M, Blomberg M, Jonsson M, Wahlund LO, Edman A, Lind K, Rosengren L, Blennow K, Wallin A. Neurofilament protein in cerebrospinal fluid: a marker of white matter changes.J Neurosci Res 66: 510\u2013516, 2001.","journal-title":"J Neurosci Res"},{"key":"10200213_CR128","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1212\/WNL.52.5.1090","volume":"52","author":"LE Rosengren","year":"1999","unstructured":"Rosengren LE, Karlsson JE, Sjogren M, Blennow K, Wallin A. Neurofilament protein levels in CSF are increased in dementia.Neurology 52: 1090\u20131093, 1999.","journal-title":"Neurology"},{"key":"10200213_CR129","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1212\/WNL.54.10.1960","volume":"54","author":"M Sjogren","year":"2000","unstructured":"Sjogren M, Rosengren L, Minthon L, Davidsson P, Blennow K, Wallin A. Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD.Neurology 54: 1960\u20131964, 2000.","journal-title":"Neurology"},{"key":"10200213_CR130","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S0304-3940(02)00047-2","volume":"320","author":"YY Hu","year":"2002","unstructured":"Hu YY, He SS, Wang XC, Duan QH, Khatoon S, Iqbal K, Grundke-Iqbal I, Wang JZ. Elevated levels of phosphorylated neurofilament proteins in cerebrospinal fluid of Alzheimer disease patients.Neurosci Lett 320: 156\u2013160, 2002.","journal-title":"Neurosci Lett"},{"key":"10200213_CR131","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1750-3639.1993.tb00723.x","volume":"3","author":"RA Nixon","year":"1993","unstructured":"Nixon RA. The regulation of neurofilament protein dynamics by phosphorylation: clues to neurofibrillary pathobiology.Brain Pathol 3: 29\u201338, 1993.","journal-title":"Brain Pathol"},{"key":"10200213_CR132","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1523\/JNEUROSCI.01-03-00300.1981","volume":"1","author":"LI Benowitz","year":"1981","unstructured":"Benowitz LI, Shashoua VE, Yoon M. Specific changes in rapidly transported proteins during regeneration of goldfish optic nerve.J Neurosci 1: 300\u2013307, 1981.","journal-title":"J Neurosci"},{"key":"10200213_CR133","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1523\/JNEUROSCI.09-03-00990.1989","volume":"9","author":"LI Benowitz","year":"1989","unstructured":"Benowitz LI, Perrone-Bizzozero NI, Finklestein SP, Bird ED. Localization of the growth-associated phosphoprotein GAP-43 (B-50, F1) in the human cerebral cortex.J Neurosci 9: 990\u2013995, 1989.","journal-title":"J Neurosci"},{"key":"10200213_CR134","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/neu.480230310","volume":"23","author":"M Mercken","year":"1992","unstructured":"Mercken M, L\u00fcbke U, Vandermeeren M, Gheuens J, Oestreicher AB. Immunocytochemical detection of the growth-associated protein B-50 by newly characterized monoclonal antibodies in human brain and muscle.J Neurobiol 23: 309\u2013321, 1992.","journal-title":"J Neurobiol"},{"key":"10200213_CR135","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/0896-6273(91)90170-5","volume":"6","author":"E Masliah","year":"1991","unstructured":"Masliah E, Mallory M, Hansen L, Alford M, Albright T, De-Teresa R, Terry R, Baudier J, Saitoh T. Patterns of aberrant sprouting in Alzheimer\u2019s disease.Neuron 6: 729\u2013739, 1991.","journal-title":"Neuron"},{"key":"10200213_CR136","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s007020070088","volume":"107","author":"N Bogdanovic","year":"2000","unstructured":"Bogdanovic N, Davidsson P, Volkmann I, Winblad B, Blennow K. Growth-associated protein GAP-43 in the frontal cortex and in the hippocampus in Alzheimer\u2019s disease: an immunohistochemical and quantitative study.J Neural Transm 107: 463\u2013478, 2000.","journal-title":"J Neural Transm"},{"key":"10200213_CR137","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1017\/S1041610298005110","volume":"10","author":"P Davidsson","year":"1998","unstructured":"Davidsson P, Blennow K. Neurochemical dissection of synaptic pathology in Alzheimer\u2019s disease.Int Psychogeriatr 10: 11\u201323, 1998.","journal-title":"Int Psychogeriatr"},{"key":"10200213_CR138","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1212\/WNL.56.1.127","volume":"56","author":"E Masliah","year":"2001","unstructured":"Masliah E, Mallory M, Alford M, DeTeresa R, Hansen LA, McKeel DW Jr et al. Altered expression of synaptic proteins occurs early during progression of Alzheimer\u2019s disease.Neurology 56: 127\u2013129, 2001.","journal-title":"Neurology"},{"key":"10200213_CR139","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/(SICI)1522-2683(19990301)20:3<431::AID-ELPS431>3.0.CO;2-2","volume":"20","author":"P Davidsson","year":"1999","unstructured":"Davidsson P, Punchades M, Blennow K. Identification of synaptic vesicle, pre- and postsynaptic proteins in human cerebrospinal fluid using liquid phase isoelectric focusing.Electrophoresis 20: 431\u2013437, 1999.","journal-title":"Electrophoresis"},{"key":"10200213_CR140","first-page":"197","volume-title":"Alzheimer\u2019s disease: biology, diagnosis and therapeutics","author":"E Vanmechelen","year":"1997","unstructured":"Vanmechelen E, Blennow K, Davidsson P, Cras P, Van de Voorde A. Combination of tau\/phospho-tau with other biochemical markers for Alzheimer CSF diagnosis and tau in CSF as marker for neurodegeneration. In: Alzheimer\u2019s disease: biology, diagnosis and therapeutics (Iqbal K, Winblad B, Nishimura T, Takeda M, Wisniewski HM, eds), pp 197\u2013203. Chichester, UK: Wiley Ltd., 1997."},{"key":"10200213_CR141","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1073\/pnas.86.2.419","volume":"86","author":"M Ozturk","year":"1989","unstructured":"Ozturk M, de la Monte S, Gross J, Wands JR. Elevated levels of an exocrine pancreatic secretory protein in Alzheimer disease brain.Proc Natl Acad Sci USA 86: 419\u2013423, 1989.","journal-title":"Proc Natl Acad Sci USA"},{"key":"10200213_CR142","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/0022-510X(92)90243-E","volume":"113","author":"SM Monte De la","year":"1992","unstructured":"De la Monte SM, Wands JR. Neuronal thread protein overexpression in brains with Alzheimer\u2019s disease lesions.J Neurol Sci 113: 152\u2013164, 1992.","journal-title":"J Neurol Sci"},{"key":"10200213_CR143","first-page":"10004","volume":"86","author":"SM Monte De la","year":"1990","unstructured":"De la Monte SM, Ozturk M, Wands JR. Enhanced expression of an exocrine pancreatic protein in Alzheimer\u2019s disease and the developing human brain.J Clin Invest 86: 10004\u201310013, 1990.","journal-title":"J Clin Invest"},{"key":"10200213_CR144","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/ana.410320606","volume":"32","author":"SM Monte De la","year":"1992","unstructured":"De la Monte SM, Volicer L, Hauser SL, Wands JR. Increased levels of neuronal thread protein in cerebrospinal fluid of patients with Alzheimer\u2019s disease.Ann Neurol 32: 733\u2013742, 1992.","journal-title":"Ann Neurol"},{"key":"10200213_CR145","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1172\/JCI112216","volume":"76","author":"J Gross","year":"1985","unstructured":"Gross J, Carlson RI, Brauer AW, Margolies MN, Warshaw AL, Wands JR. Isolation, characterization, and distribution of an unusual pancreatic human secretory protein.J Clin Invest 76: 2115\u20132126, 1985.","journal-title":"J Clin Invest"},{"key":"10200213_CR146","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1006\/neur.1995.0023","volume":"4","author":"K Blennow","year":"1995","unstructured":"Blennow K, Wallin A, Chong JK. Cerebrospinal fluid \u201cneuronal thread protein\u201d comes from serum by passage over the blood-brain barrier.Neurodegeneration 4: 187\u2013193, 1995.","journal-title":"Neurodegeneration"},{"key":"10200213_CR147","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1172\/JCI119864","volume":"100","author":"SM Monte","year":"1997","unstructured":"Monte SM, Ghanbari K, Frey WH, Beheshti I, Averback P, Hauser SL et al. Characterization of the AD7C-NTP cDNA expression in Alzheimer\u2019s disease and measurement of a 41-kD protein in cerebrospinal fluid.J Clin Invest 100: 3093\u20133104, 1997.","journal-title":"J Clin Invest"},{"key":"10200213_CR148","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/(SICI)1098-2825(1998)12:4<223::AID-JCLA6>3.0.CO;2-8","volume":"12","author":"K Ghanbari","year":"1998","unstructured":"Ghanbari K, Ghanbari H. A sandwich enzyme immunoassay for measuring AD7C-NTP as an Alzheimer\u2019s disease marker: AD7C test.J Clin Lab Anal 12: 223\u2013226, 1998.","journal-title":"J Clin Lab Anal"}],"container-title":["NeuroRX"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1602\/neurorx.1.2.213","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,12]],"date-time":"2024-01-12T20:23:26Z","timestamp":1705091006000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1602\/neurorx.1.2.213"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,4]]},"references-count":148,"aliases":["10.1007\/bf03206605"],"journal-issue":{"issue":"2","published-print":{"date-parts":[[2004,4]]}},"alternative-id":["10200213"],"URL":"https:\/\/doi.org\/10.1602\/neurorx.1.2.213","relation":{},"ISSN":["1545-5343"],"issn-type":[{"value":"1545-5343","type":"print"}],"subject":[],"published":{"date-parts":[[2004,4]]}}}